Sagittarius Life Science (3205) — Cash Flow-to-Debt Ratio
Sagittarius Life Science (3205) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of NT$-21.27 Million could theoretically repay -1% of its total liabilities (NT$26.91 Million) in one year. See 3205 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sagittarius Life Science Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Sagittarius Life Science across 11 annual periods. For the full cash flow conversion analysis, see Sagittarius Life Science (3205) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sagittarius Life Science (2015–2025)
Year-by-year debt coverage analysis for Sagittarius Life Science. Check Sagittarius Life Science earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.34x | NT$-36.05 Million | NT$26.91 Million | ▼ -201.4% |
| 2024 | -0.44x | NT$-44.48 Million | NT$100.07 Million | ▲ +11.7% |
| 2023 | -0.50x | NT$-69.37 Million | NT$137.82 Million | ▼ -17.7% |
| 2022 | -0.43x | NT$-52.89 Million | NT$123.70 Million | ▼ -111.0% |
| 2021 | -0.20x | NT$-29.18 Million | NT$144.03 Million | ▲ +50.4% |
| 2020 | -0.41x | NT$-62.24 Million | NT$152.36 Million | ▲ +46.4% |
| 2019 | -0.76x | NT$-104.50 Million | NT$137.09 Million | ▼ -27.0% |
| 2018 | -0.60x | NT$-57.86 Million | NT$96.38 Million | ▼ -150.2% |
| 2017 | -0.24x | NT$-23.31 Million | NT$97.16 Million | ▼ -113.4% |
| 2016 | 1.80x | NT$360.37 Million | NT$200.51 Million | ▲ +215.0% |
| 2015 | 0.57x | NT$237.94 Million | NT$416.95 Million | — |